Last reviewed · How we verify
Deoxyspergualin
Deoxyspergualin is a Small molecule drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently in discontinued development. Also known as: Spanidin, gusperimus hydrochloride.
At a glance
| Generic name | Deoxyspergualin |
|---|---|
| Also known as | Spanidin, gusperimus hydrochloride |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Randomised, Evaluator-Blinded, Multicentre, International, Parallel-Group, Active-Controlled Clinical Trial of Gusperimus Versus Conventional Therapy in Relapse of Granulomatosis With Polyangiitis (We (Phase 3)
- Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes (CIT-03) (Phase 2)
- Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis (Phase 2)
- Pilot Study of Cycling Treatment of Deoxyspergualin in Biopsy-proven Chronic Rejection of Kidney Transplantation (NA)
- Tolerance Induction Following Human Renal Transplantation Using Treatment With a Humanized Monoclonal Antibody Against CD52 (Campath-1H) (Phase 2)
- Safety and Efficacy Study on Deoxyspergualin (NKT-01) in Patients With Uncontrolled Lupus Nephritis Receiving Oral Corticosteroids and Prior Treatment of Standard Immunosuppressive Therapy (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Deoxyspergualin CI brief — competitive landscape report
- Deoxyspergualin updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about Deoxyspergualin
What is Deoxyspergualin?
Deoxyspergualin is a Small molecule drug developed by National Institute of Allergy and Infectious Diseases (NIAID).
Who makes Deoxyspergualin?
Deoxyspergualin is developed by National Institute of Allergy and Infectious Diseases (NIAID) (see full National Institute of Allergy and Infectious Diseases (NIAID) pipeline at /company/national-institute-of-allergy-and-infectious-diseases-niaid).
Is Deoxyspergualin also known as anything else?
Deoxyspergualin is also known as Spanidin, gusperimus hydrochloride.
What development phase is Deoxyspergualin in?
Deoxyspergualin is in discontinued.
Related
- Manufacturer: National Institute of Allergy and Infectious Diseases (NIAID) — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Spanidin, gusperimus hydrochloride
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing